Financing Comes Full Circle; R&DLP Resurgence in Works?
By Trista Morrison
Thursday, November 11, 2010
Private equity-backed royalty deals, a relatively new edition to the biotech world, have already evolved from financing vehicle to strategic portfolio management tool. Now they seem to be evolving again, this time toward earlier-stage project financing, and they're starting to look a little like one of the oldest tricks in biotech's playbook: the Research and Development Limited Partnership (R&DLP). (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.